Q1 2023 Results
Company overview
Financial review
Innovation: Pipeline overview
Financial performance
Cardiovascular
Immunology
Piqray® - PI3K-alpha inhibitor
NCT04729387 EPIK-O (CBYL719K12301)
Ovarian Cancer
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
Indication
Phase
Phase 3
Patients
358
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Progression Free Survival (PFS) based on Blinded Independent Review
Committee (BIRC) assessment using RECIST 1.1 criteria
Arm 1 Experimental: Alpelisib+olaparib: Alpelisib 200 mg orally once daily and
olaparib 200 mg orally twice daily on a continuous dosing schedule
Arm 2 Active Comparator: Paclitaxel or PLD. Investigator's choice of one of 2
single agent cytotoxic chemotherapies: Paclitaxel 80 mg/m2 intravenously
weekly or Pegylated liposomal Doxorubicin (PLD) 40-50 mg/m2 (physician
discretion) intravenously every 28 days.
Patients with platinum resistant or refractory high-grade serous ovarian cancer,
with no germline BRCA mutation detected
Readout
Milestone(s)
2023
Publication
TBD
76 Investor Relations | Q1 2023 Results
References
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation